Design the trial with every precedent in view.
Endpoints, eligibility criteria, comparators and results from registered trials and their publications, lined up side by side.
| Trial | Drug | Primary endpoint | Source |
|---|---|---|---|
| MAESTRO-NASH | Resmetirom | MASH resolution with no worsening of fibrosis; fibrosis improvement of at least one stage with no worsening of NAS | Harrison et al., NEJM, 2024 |
| ESSENCE | Semaglutide | Histology at week 72 (part 1); clinical outcomes (part 2) | ClinicalTrials.gov |
Questions
The questions at this stage.
- Which primary endpoints have phase 3 trials in MASH used?
- What eligibility criteria do recent trials in this indication share?
- Which trials missed on this endpoint, and why?
- What comparators do regulators and payers expect here?
Related use cases
Also at this stage.
The narrower questions teams bring to this stage.
Endpoint benchmarking
Primary and secondary endpoints across every registered trial in an indication.
Eligibility criteria
Inclusion and exclusion criteria that recent trials share, and where they differ.
Comparator selection
Standard of care and active comparators used in past trials and labels.
Biomarker-stratified designs
Trials that enrolled by biomarker, and how those subgroups read out.
Competitor trial tracking
New registrations, status changes and results for a target or indication.
Applications
What teams build.
Endpoint benchmarking tools
Compare primary and secondary endpoints across every trial in an indication.
Protocol drafting copilots
Draft eligibility and endpoint sections with the precedent trials cited.
Competitive trial trackers
Follow competitor trials from registration to readout.
Before the protocol locks
Benchmark your endpoints against every trial in the indication.
Primary endpoints, eligibility and outcomes from registered trials and their publications, in one cited table.